Metabolism and pharmacokinetics of SP-8356, a novel (1S)-(−)-verbenone derivative, in rats and dogs and its implications in humans

Yuanyuan Zhou, Mun Hwan Oh, Yeon Joon Kim, Eun Yeong Kim, Jinhong Kang, Sung Chung, Chung Ju, Won Ki Kim, Kiho Lee

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


(1S,5R)-4-((E)-3,4-dihydroxy-5-methoxystryryl)-6,6-dimethylbicylco[3.1.1]hept-3-en-2-one (SP-8356) is a novel (1S)-(−)-verbenone derivative that is currently in preclinical development for the treatment of ischemic stroke and atherosclerosis. This report aimed at characterization of the metabolism and pharmacokinetic properties of SP-8356. Following intravenous dose in rats and dogs, plasma concentrations of SP-8356 declined rapidly with high clearance (CL) and short half-life; after oral administration in both species, its plasma levels were below the quantitation limit. Fourteen circulating metabolites, formed by mono-oxygenation, demethylation, glucuronidation, catechol O-methylation, sulfation and oxidation (bioactivation) followed by glutathione (GSH) conjugation, were tentatively identified in both species. Urinary excretion of SP-8356 appeared to be minimal in rats, compared to its metabolites. GSH conjugate of SP-8356 was also formed during incubation with rat liver S9 fraction consistent with oxidative bioactivation; this bioactivation was almost completely inhibited by the cofactors for glucuronidation, sulfation and methylation, indicating that it may be abolished by competing metabolic reactions in the body. The human pharmacokinetics of SP-8356 was predicted to be similar to that of the animals based on the current in vitro metabolic stability results. In summary, rapid phase II metabolism appears to be mainly responsible for its suboptimal pharmacokinetics, such as high CL and low oral absorption. Because of competing metabolic reactions, potential safety risks related to SP-8356 bioactivation may be low.

Original languageEnglish
Article number25081775
Issue number8
Publication statusPublished - 2020 Apr 1


  • Bioactivation
  • Conjugation
  • Metabolism
  • Pharmacokinetics
  • SP-8356

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry


Dive into the research topics of 'Metabolism and pharmacokinetics of SP-8356, a novel (1S)-(−)-verbenone derivative, in rats and dogs and its implications in humans'. Together they form a unique fingerprint.

Cite this